Online citations, reference lists, and bibliographies.
← Back to Search

Bevacizumab 15mg/kg Plus Cisplatin-pemetrexed (CP) Triplet Versus CP Doublet In Malignant Pleural Mesothelioma (MPM): Results Of The IFCT-GFPC-0701 MAPS Randomized Phase 3 Trial.

G. Zalcman, J. Mazières, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I. Monnet, V. Gounant, H. Janicot, R. Gervais, C. Locher, B. Milleron, Q. Tran, M. Lebitasy, F. Morin, C. Creveuil, J. Parienti, A. Scherpereel, French Cooperative Thoracic Intergroup
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
7500 Background: MPM median overall survival (OS) did not exceed 13 months with pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular endothelial growth factor is a potent mitogen for MPM cells. Methods: In this French multicenter randomized phase 3 trial, eligible patients had unresectable, histologically proved MPM, age < 76, no prior chemo, PS 0-2, no thrombosis, nor bleeding. Randomized patients (1:1) received pem 500 mg/m2, CDDP 75 mg/m2 at D1, with (arm B) or without bevacizumab (arm A), 15 mg/kg Q21D, for 6 cycles. Arm B non-progressive patients received bevacizumab maintenance therapy until progression or toxicity. Primary endpoint was OS. 445 patients were to be randomized, and 385 events observed, to show a significant OS improvement, with 80% statistical power, 5% a-risk. Results: From Feb. 2008 to Jan. 2014, 448 patients were included in 73 centers. Males: 75.4%, median age: 65.7 years (range 34.7-75.9), PS 0-1: 96.7%. The IDMC recommended a second interim anal...



This paper is referenced by
10.1016/S1877-1203(16)30030-1
Comment offrir à tous un accès aux thérapeutiques innovantes
J. Cadranel (2015)
10.1007/978-1-4471-2230-2
Integrated palliative care of respiratory disease
Stephen J. Bourke (2013)
10.1007/978-3-030-18944-0_7
Malignant Pleural Effusions and Mesothelioma
David Cooper (2019)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.2217/LMT.15.32
New directions in mesothelioma treatment
Anna K. Nowak (2015)
10.1007/s10405-015-0012-3
Seltene thorakale Tumorentitäten
Armin Frille (2015)
10.1080/14656566.2016.1176145
Advances in treatment of mesothelioma
C. Maggioni (2016)
10.1016/J.BULCAN.2015.11.006
L’année 2015 à travers le regard du comité de rédaction du Bulletin du cancer
N. Magne (2016)
10.1007/978-3-030-18944-0
Integrated Palliative Care of Respiratory Disease
Stephen J. Bourke (2019)
10.1007/s12094-015-1464-y
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
D. Márquez-Medina (2015)
10.1016/j.critrevonc.2016.08.011
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
G. Bronte (2016)
10.1002/1878-0261.12150
A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
K. Schelch (2018)
10.2217/LMT.15.23
Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma
Alistair M. Cook (2015)
10.1093/annonc/mdw427
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
J. Soria (2016)
10.1177/1753465816628800
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
10.1158/1078-0432.CCR-16-0844
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Licun Wu (2016)
10.1016/j.jtho.2015.09.004
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma
Laurent Greillier (2016)
10.5301/tj.5000436
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma
Matthew Wu (2015)
10.1007/7355_2016_28
Inhibitors of Vascular Endothelial Growth Factor Receptor
Philip A. Harris (2017)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1016/S1877-1203(16)30034-9
Mésothéliomes pleuraux malins
Arnaud Scherpereel (2015)
10.1186/s12885-015-1881-x
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
Christine Raynaud (2015)
10.2217/fon.15.225
Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history?
Tom Treasure (2015)
10.1136/thoraxjnl-2017-211416
Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
I. Woolhouse (2018)
10.1016/j.jtho.2016.01.014
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
Wieneke A. Buikhuisen (2016)
Semantic Scholar Logo Some data provided by SemanticScholar